For children aged 3 years and older with chronic hepatitis C, when considering antiviral therapy, the combination of glecaprevir (an NS3/4A protease inhibitor)+pibrentasvir (an NS5A protein inhibitor) (Maviret°) is often the first choice, because it has high virological efficacy irrespective of the virus genotype. The duration of treatment is only 8 weeks in patients who have never received an antiviral directed against hepatitis C (1). The combination of sofosbuvir (an NS5B RNA poly-merase inhibitor) + velpatasvir (an NS5A protein inhibitor) (Epclusa° - Gilead Sciences), which was already authorised from the age of 6 years, has now also been authorised for use from 3 years of age. The duration of treatment with this combination is 12 weeks (2). Evaluation is based on one non-comparative trial in 41 children aged 3 to 5 years who had not yet received antiviral treatment for hepatitis C and who were most often infected with a genotype-1 virus.
展开▼
